Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Reck, Martin; Rodríguez‐Abreu, Delvys; Robinson, Andrew; Hui, Rina; Csőszi, Tibor; Fülöp, Andrea; Gottfried, Maya; Peled, Nir; Tafreshi, Ali; Cuffe, Sinéad; O’Brien, Mary; Rao, Suman; Hotta, Katsuyuki; A. Leiby, Melanie; M. Lubiniecki, Gregory; Shentu, Yue; Rangwala, Reshma; R. Brahmer, Julie

doi:10.1056/nejmoa1606774

Public

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Oct 9, 2016

Authors:

Martin Reck

Delvys Rodríguez‐Abreu

Andrew Robinson

Abstract

BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3 trial, we ...

Subject

Pembrolizumab

Medicine

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!